You need to enable JavaScript to run this app.
Recon: House bill proposes changes in FDA’s accelerated approval program for drugs; Novartis signs $1.7b option agreement with Voyager Therapeutics
Recon
Joanne S. Eglovitch
Global
ReconJoanne S. Eglovitch
GlobalReconJoanne S. EglovitchGlobal